Skip to content

Irisin

An exercise-induced myokine that promotes browning of white adipose tissue, enhances metabolism, and shows neuroprotective effects — though bioavailability and clinical translation remain challenging.

DEmergingLimited Data
Last updated 8 citations

What is Irisin?

Irisin is an endogenous myokine — a signaling molecule produced by skeletal muscle during exercise. It is generated by proteolytic cleavage of FNDC5 (fibronectin type III domain-containing protein 5), a PGC-1α-regulated membrane protein. First identified by Spiegelman et al. in 2012, irisin drew enormous scientific and public attention as a candidate "exercise hormone" — a molecule that might replicate some of exercise's metabolic benefits by promoting the browning of white adipose tissue (converting energy-storing fat into energy-burning fat). More than a decade later, irisin remains an active research area with legitimate mechanistic findings but substantial controversy over quantification, bioactivity in humans, and therapeutic feasibility.

What Irisin Is Investigated For

Irisin is studied primarily as the exercise-induced myokine responsible for browning of white adipose tissue, with additional preclinical signals in bone formation, neuroprotection (particularly in Alzheimer's models), and glucose regulation. The strongest evidence is for the muscle-PGC-1α-FNDC5-irisin axis itself — the molecule is real, the receptor (integrin αV/β5) is identified, and rodent studies consistently show exogenous irisin induces UCP1 expression and improves glucose tolerance. Human translation is where the story thins: early human quantification was plagued by unreliable antibodies, exercise-induced elevation is inconsistent across studies, and there is no human RCT of exogenous irisin administration for any indication. Irisin is a ~112-residue glycosylated peptide with poor oral bioavailability and no approved therapeutic product, so the practical way to raise levels remains the input that generated the biology in the first place — exercise, particularly resistance training and HIIT. Research-chemical 'irisin' is of unverified purity and is not a validated therapeutic.

White adipose tissue browning and thermogenesis
Moderate70%
Muscle-metabolic signaling during exercise
Moderate70%
Bone density and osteoporosis support
Emerging50%
Neuroprotection (Alzheimer's disease preclinical models)
Emerging50%
Glucose regulation and insulin sensitivity
Emerging50%

How It Works

When you exercise, your muscles release irisin — a hormone that tells white fat cells (which store energy) to become more like brown fat cells (which burn energy). It also appears to signal bone, brain, and metabolic tissues in ways that may replicate some benefits of exercise. The catch: taking irisin as a pill or injection doesn't work well, and the amount your body makes naturally varies a lot between people and training types.

Irisin is produced when exercise activates PGC-1α (a master metabolic transcription coactivator) in skeletal muscle, upregulating FNDC5. The FNDC5 membrane protein is proteolytically cleaved and secreted as a glycosylated ~12 kDa fragment. Irisin binds integrin αV/β5 receptors on target cells, activating downstream signaling that includes p38 MAPK and ERK pathways. In white adipocytes, this induces expression of UCP1 (uncoupling protein 1) and other thermogenic markers, converting them to a "beige" or brown-like phenotype capable of non-shivering thermogenesis. Irisin also acts on osteoblasts (promoting bone formation), hippocampal neurons (increasing BDNF expression, neurogenesis), and pancreatic beta cells (supporting insulin secretion). A 2026 Aging Cell paper extended the brain-axis evidence into humans for the first time, showing serum irisin correlates with hippocampal subfield structure in 74 healthy older adults — a cross-sectional but human signal that partially translates the prior preclinical Alzheimer's findings. A separate 2026 Nature Immunology highlight points to a novel immunological mechanism beyond the metabolic/CNS axis: irisin appears to support ST2+ regulatory T cell populations, opening an early-stage thread on irisin and immune homeostasis. The controversy around irisin centers on the magnitude of these effects at physiologic concentrations — preclinical studies often use doses orders of magnitude higher than endogenous circulating levels, making translation to therapeutic benefit uncertain.

Evidence Snapshot

Overall Confidence45%

Human Clinical Evidence

Limited direct interventional data — irisin is primarily studied as a biomarker, not an intervention. Observational studies link circulating irisin with muscle mass, metabolic health, and exercise response. No human RCT of exogenous irisin administration.

Animal / Preclinical

Moderate to strong. Multiple rodent studies show exogenous irisin improves glucose tolerance, induces adipose browning, protects against neurodegeneration in Alzheimer's models, and supports bone formation.

Mechanistic Rationale

Strong for the muscle-PGC-1α-FNDC5 axis. Moderate for downstream effects in adipose, bone, and brain — the receptor identity (integrin αV/β5) was established in 2018 but effect sizes at physiologic concentrations remain debated.

Forms & Administration

Irisin is not available as an approved therapy or clinical product. Research grade recombinant irisin is used in laboratory studies. The established way to raise endogenous irisin is regular exercise, particularly high-intensity and resistance training. Adequate protein intake and sleep also support PGC-1α/FNDC5 expression.

Monitoring & Measurement

Bloodwork & Labs

  • Serum irisin via validated LC-MS/MS — the only assay with published analytical rigor; ELISA kits for irisin have documented specificity problems and are generally not trustworthy
  • Fasting glucose, fasting insulin (HOMA-IR), HbA1c
  • Lipid panel
  • ALT and AST

Functional & Performance Tests

  • VO2 max (lab test or validated wearable) — irisin's endogenous rise is exercise-linked, so a fitness trajectory anchors interpretation
  • DEXA scan — body composition, especially fat-mass and lean-mass changes
  • Resting metabolic rate via indirect calorimetry if accessible

When to Test

Baseline, 12 weeks, 24 weeks.

Interpretation & Notes

Irisin is the most assay-sensitive peptide in this cluster: a large fraction of published 'irisin responds to X' literature used ELISA kits that failed independent validation, which is why LC-MS/MS is the only serum measurement worth paying for. Direct exogenous irisin peptide is not a routine research-chemical product, and what does exist has essentially no human clinical data — if you are supplementing, you are at the earliest edge of a hypothesis. The most honest self-measurement is exercise-centric: measured aerobic training reliably raises endogenous irisin, so tracking VO2 max and body composition alongside a disciplined training protocol tells you whether the broader pathway is moving. Standard metabolic panels via LabCorp/Quest direct-to-consumer; LC-MS/MS irisin testing is specialty and often research-only.

Common Questions

Safety Profile

Safety Information

Common Side Effects

Not applicable in clinical use — irisin is not administered therapeutically in approved contexts

Cautions

  • No clinical safety database in humans as an exogenous therapy
  • Quantification of endogenous irisin has been historically unreliable
  • Research chemicals sold as 'irisin' online are of unverified purity and not intended for human use

What We Don't Know

Long-term safety of exogenous irisin administration is unstudied. Whether supra-physiologic irisin levels would recapitulate the benefits of exercise or produce off-target effects is unknown.

Published Research

8 studies

Irisin supports ST2+ Treg cells

ReviewPMID: 42062508

The Myokine Irisin Represents an Indirect Pathway Linking Exercise to Hippocampal Subfields Relevant to Alzheimer's Disease and Neurogenesis

First human translation data linking serum irisin to hippocampal subfield structure — 74 healthy older adults with structural MRI, exercise questionnaires, and fasting irisin measurement. Mediation analyses tested whether irisin underlies the exercise-to-hippocampus pathway in humans, partially translating the Lourenco 2019 preclinical Alzheimer's findings into observational human data.

Clinical TrialPMID: 42033046

The role and underlying mechanisms of irisin in exercise-mediated cardiovascular protection

ReviewPMID: 39494293

Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models

PreclinicalPMID: 30617325

Detection and quantitation of circulating human irisin by tandem mass spectrometry

The Jedrychowski et al. 2015 Cell Metabolism paper resolving the long-running ELISA controversy — used mass spectrometry to definitively confirm irisin circulates in humans and increases with exercise.

Original ResearchPMID: 26278051

Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue

Clinical TrialPMID: 24297848

A PGC1α-dependent myokine that drives browning of white fat and thermogenesis

The Boström et al. 2012 Nature paper — the landmark discovery that named irisin and identified it as the PGC1α-dependent exercise-induced myokine driving white-to-brown fat conversion.

Original ResearchPMID: 22237023

Irisin: A Multifaceted Hormone Bridging Exercise and Disease Pathophysiology

Review

Quick Facts

Class
Myokine
Tier
D
Evidence
Emerging
Safety
Limited Data
Updated
May 2026
Citations
8PubMed

Also known as

FNDC5 fragmentExercise hormoneFibronectin type III domain-containing protein 5

Tags

MyokineMetabolismExerciseAdipose BrowningNeuroprotection

Evidence Score

Overall Confidence45%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.